Delayed β-cell response and glucose intolerance in young women with Turner syndrome

Britta E Hjerrild, Jens J Holst, Claus B Juhl, Jens S Christiansen, Ole Schmitz, Claus H Gravholt, Britta E Hjerrild, Jens J Holst, Claus B Juhl, Jens S Christiansen, Ole Schmitz, Claus H Gravholt

Abstract

Background: To investigate glucose homeostasis in detail in Turner syndrome (TS), where impaired glucose tolerance (IGT) and type 2 diabetes are frequent.

Methods: Cross sectional study of women with Turner syndrome (TS)(n = 13) and age and body mass index matched controls (C) (n = 13), evaluated by glucose tolerance (oral and intravenous glucose tolerance test (OGTT and IVGTT)), insulin sensitivity (hyperinsulinemic, euglycemic clamp), beta-cell function (hyperglycaemic clamp, arginine and GLP-1 stimulation) and insulin pulsatility.

Results: Fasting glucose and insulin levels were similar. Higher glucose responses was seen in TS during OGTT and IVGTT, persisting after correction for body weight or muscle mass, while insulin responses were similar in TS and C, despite the higher glucose level in TS, leading to an insufficient increase in insulin response during dynamic testing. Insulin sensitivity was comparable in the two groups (TS vs. control: 8.6 ± 1.8 vs. 8.9 ± 1.8 mg/kg*30 min; p = 0.6), and the insulin responses to dynamic β-cell function tests were similar. Insulin secretion patterns examined by deconvolution analysis, approximate entropy, spectral analysis and autocorrelation analysis were similar. In addition we found low IGF-I, higher levels of cortisol and norepinephrine and an increased waist-hip ratio in TS.

Conclusions: Young normal weight TS women show significant glucose intolerance in spite of normal insulin secretion during hyperglycaemic clamping and normal insulin sensitivity. We recommend regularly testing for diabetes in TS.

Trial registration: Registered with http://clinicaltrials.com, ID nr: NCT00419107.

Figures

Figure 1
Figure 1
Study design of day 1, 2 and 3. On day 1 an oral glucose tolerance test (OGTT), as well as DEXA scan and exercise test was performed. On day 2, we did the intravenous glucose tolerance test, followed by a hyperinsulinemic euglycemic clamp. Energy expenditure was assessed in fasting condition and during the steady state period of the clamp. On day 3, we performed insulin pulsatility testing followed by a graded hyperglycaemic clamp with arginine bolus and finally GLP-1 bolus to stress the β-cell maximally (for details - see Materials and Method section).
Figure 2
Figure 2
Levels of glucose, insulin, glucagon-like. peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP); free fatty acids (FFA), triglycerides, Insulin-like growth factor 1(IGF-1) and growth hormone (GH) during the 2-hour oral glucose tolerance test. P-values are based on differences between TS and controls based on AUC and given in the figure. All mean ± SD.
Figure 3
Figure 3
Glucose and insulin levels (mean ± SD) during the hyperglycemic clamp (60-240 minutes) (A), arginine (240-270 minutes) (B) and GLP-1 stimulation (270-300 minutes) (C). P-values are given in the figure.
Figure 4
Figure 4
Growth hormone (GH) and free fatty acid (FFA) during the hyperinsulinemic clamp period (60-240 minutes). Glucagon levels during the arginine and GLP-1 stimulation (240-300 minutes), and GLP-1 levels during the GLP-1 infusion period (270-300 minutes). All numbers are presented as mean ± SD. P-values are given in the figure.

References

    1. Forbes AP, Engel E. The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metabolism. 1963;12:428–439.
    1. Nielsen J, Johansen K, Yde H. The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinol Copenh. 1969;62:251–269.
    1. Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, Amiel S, Press M, Tamborlane WV. Insulin resistance: an early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab. 1991;72:832–836. doi: 10.1210/jcem-72-4-832.
    1. Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. Diabetes Care. 1998;21:1062–1070. doi: 10.2337/diacare.21.7.1062.
    1. Bakalov VK, Cooley MM, Quon MJ, Luo ML, Yanovski JA, Nelson LM, Sullivan G, Bondy CA. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab. 2004;89:3516–3520. doi: 10.1210/jc.2004-0122.
    1. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51:147–158. doi: 10.1016/S0895-4356(97)00237-0.
    1. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in women with turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab. 2008;93:4735–4742. doi: 10.1210/jc.2008-1049.
    1. Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91:3897–3902. doi: 10.1210/jc.2006-0558.
    1. Salgin B, Amin R, Yuen K, Williams RM, Murgatroyd P, Dunger DB. Insulin resistance is an intrinsic defect independent of fat mass in women with Turner's syndrome. Horm Res. 2006;65:69–75. doi: 10.1159/000090907.
    1. Abrahamsen B, Gram J, Hansen TB, Beck NH. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. Bone. 1995;16:385–390. doi: 10.1016/8756-3282(94)00054-9.
    1. Ferrannini E. Equations and assumptions of indirect calorimetry: some special problems. 1992. pp. 1–17.
    1. Tripathy D, Wessman Y, Gullstrom M, Tuomi T, Groop L. Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test: results with the Botnia clamp. Diabetes Care. 2003;26:1395–1401. doi: 10.2337/diacare.26.5.1395.
    1. Veldhuis JD, Carlson ML, Johnson ML. The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA. 1987;84:7686–7690. doi: 10.1073/pnas.84.21.7686.
    1. Porksen N, Nyholm B, Veldhuis JD, Butler PC, Schmitz O. In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts. Am J Physiol. 1997;273:E908–14.
    1. Pincus SM. Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA. 1991;88:2297–2301. doi: 10.1073/pnas.88.6.2297.
    1. Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul. 1995;5:169–176.
    1. Carstensen E, Yudkin JS. Platelet catecholamine concentrations after short-term stress in normal subjects. Clin Sci (Lond) 1994;86:35–41.
    1. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism. 1994;43:104–108. doi: 10.1016/0026-0495(94)90164-3.
    1. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85:3575–3581. doi: 10.1210/jc.85.10.3575.
    1. Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab. 2001;86:4166–4170. doi: 10.1210/jc.86.9.4166.
    1. Ostberg JE, Attar MJ, Mohamed-Ali V, Conway GS. Adipokine dysregulation in Turner syndrome: comparison of circulating interleukin-6 and leptin concentrations with measures of adiposity and C-reactive protein. J Clin Endocrinol Metab. 2005;90:2948–2953. doi: 10.1210/jc.2004-1966.
    1. Stoppoloni G, Prisco F, Alfano C, Iafusco D, Marrazzo G, Paolisso G. Characteristics of insulin resistance in Turner syndrome. Diabete Metab. 1990;16:267–271.
    1. Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab. 2009;94:3289–3296. doi: 10.1210/jc.2009-0384.
    1. Vilsboll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care. 2000;23:807–812. doi: 10.2337/diacare.23.6.807.
    1. Holl RW, Kunze D, Etzrodt H, Teller W, Heinze E. Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediatr. 1994;153:11–16. doi: 10.1007/BF02000780.
    1. Gravholt CH, Leth-Larsen R, Lauridsen AL, Thiel S, Hansen TK, Holmskov U, Naeraa RW, Christiansen JS. The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. Eur J Endocrinol. 2004;150:355–362. doi: 10.1530/eje.0.1500355.
    1. Mortensen KH, Cleemann L, Hjerrild BE, Nexo E, Locht H, Jeppesen EM, Gravholt CH. Increased prevalence of autoimmunity in Turner syndrome--influence of age. Clin Exp Immunol. 2009;156:205–210. doi: 10.1111/j.1365-2249.2009.03895.x.
    1. Jorgensen KT, Rostgaard K, Bache I, Biggar RJ, Nielsen NM, Tommerup N, Frisch M. Autoimmune diseases in women with Turner's Syndrome. Arthritis Rheum. 2010;62:658–666. doi: 10.1002/art.27270.
    1. Bianco B, Verreschi IT, Oliveira KC, Guedes AD, Galera BB, Galera MF, Barbosa CP, Lipay MV. PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome. Scand J Immunol. 2010;72:256–259. doi: 10.1111/j.1365-3083.2010.02438.x.
    1. Gravholt CH, Frystyk J, Flyvbjerg A, Ørskov H, Christiansen JS. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am J Physiol. 2001;280:E308–E314.
    1. Gravholt CH, Hjerrild BE, Mosekilde L, Hansen TK, Rasmussen LM, Frystyk J, Flyvbjerg A, Christiansen JS. Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol. 2006;155:583–592. doi: 10.1530/eje.1.02267.
    1. Gravholt CH, Chen JW, Oxvig C, Overgaard MT, Christiansen JS, Frystyk J, Flyvbjerg A. The GH-IGF-IGFBP axis is changed in Turner syndrome: Partial normalization by HRT. Growth Horm IGF Res. 2006;16:332–339. doi: 10.1016/j.ghir.2006.09.001.
    1. Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2008;93:2109–2114. doi: 10.1210/jc.2007-2266.
    1. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab. 2008;93:1702–1710. doi: 10.1210/jc.2007-2193.
    1. Zuckerman-Levin N, Zinder O, Greenberg A, Levin M, Jacob G, Hochberg Z. Physiological and catecholamine response to sympathetic stimulation in turner syndrome. Clin Endocrinol (Oxf) 2006;64:410–415. doi: 10.1111/j.1365-2265.2006.02483.x.
    1. Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf) 1999;51:497–502. doi: 10.1046/j.1365-2265.1999.00841.x.
    1. Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab. 2003;88:3794–3800. doi: 10.1210/jc.2002-021181.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa